GC
JSPR icon

Grace Capital’s Jasper Therapeutics JSPR Stock Holding History

Grace Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1.71M Buy
+21,811
New +$2.04M 1.02% 27

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grace Capital's JSPR Position: Q4 2021 in Review

Grace Capital opened a new position in Jasper Therapeutics (JSPR) in Q4 2021: 21,811 shares worth $1.71M. The stake represents 1.02% of the portfolio and ranks #27 among its holdings.

25 funds tracked by Wall St. Rank hold JSPR as of Q4 2021.

  • Grace Capital held 21,811 shares of Jasper Therapeutics worth $1.71M as of Q4 2021.
  • Jasper Therapeutics was a new Grace Capital position in Q4 2021.
  • Jasper Therapeutics made up 1.02% of Grace Capital's portfolio in Q4 2021, its #27 holding.
  • 25 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2021.

Based on Grace Capital's 13F filing for Q4 2021, filed 2 Feb 2022.